Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons

David L. Thomas; John G. Bartlett; Marion G. Peters; Kenneth E. Sherman; Mark S. Sulkowski; Paul A. Pham

doi:10.1093/cid/cir882

Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons

David L. Thomas, John G. Bartlett, Marion G. Peters, Kenneth E. Sherman, Mark S. Sulkowski, Paul A. Pham

School of Medicine

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

In May 2011, hepatitis C virus (HCV) protease inhibitors (PIs) were approved by the US Food and Drug Administration to treat persons with genotype 1 chronic hepatitis C virus (HCV) infection, but not those dually infected with human immunodeficiency virus (HIV). Although critical safety and efficacy data are lacking, the availability of the drugs and substantial medical need justify the off-label use of HCV PIs in select HIV/HCV-coinfected persons. Pending results of ongoing investigations, this article represents provisional guidance on the use of HCV PIs in HIV-infected persons.

Original language	English (US)
Pages (from-to)	979-983
Number of pages	5
Journal	Clinical Infectious Diseases
Volume	54
Issue number	7
DOIs	https://doi.org/10.1093/cid/cir882
State	Published - Apr 1 2012

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/cir882

Cite this

@article{8d8ac8ac1cfa4f338a86fc563c3e39aa,

title = "Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons",

abstract = "In May 2011, hepatitis C virus (HCV) protease inhibitors (PIs) were approved by the US Food and Drug Administration to treat persons with genotype 1 chronic hepatitis C virus (HCV) infection, but not those dually infected with human immunodeficiency virus (HIV). Although critical safety and efficacy data are lacking, the availability of the drugs and substantial medical need justify the off-label use of HCV PIs in select HIV/HCV-coinfected persons. Pending results of ongoing investigations, this article represents provisional guidance on the use of HCV PIs in HIV-infected persons.",

author = "Thomas, {David L.} and Bartlett, {John G.} and Peters, {Marion G.} and Sherman, {Kenneth E.} and Sulkowski, {Mark S.} and Pham, {Paul A.}",

note = "Funding Information: Financial support. This research was supported in part by US Public Health Service grants (R01016027 to D. T. and K24DK070528 to K. E. S.).",

year = "2012",

month = apr,

day = "1",

doi = "10.1093/cid/cir882",

language = "English (US)",

volume = "54",

pages = "979--983",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons

AU - Thomas, David L.

AU - Bartlett, John G.

AU - Peters, Marion G.

AU - Sherman, Kenneth E.

AU - Sulkowski, Mark S.

AU - Pham, Paul A.

N1 - Funding Information: Financial support. This research was supported in part by US Public Health Service grants (R01016027 to D. T. and K24DK070528 to K. E. S.).

PY - 2012/4/1

Y1 - 2012/4/1

N2 - In May 2011, hepatitis C virus (HCV) protease inhibitors (PIs) were approved by the US Food and Drug Administration to treat persons with genotype 1 chronic hepatitis C virus (HCV) infection, but not those dually infected with human immunodeficiency virus (HIV). Although critical safety and efficacy data are lacking, the availability of the drugs and substantial medical need justify the off-label use of HCV PIs in select HIV/HCV-coinfected persons. Pending results of ongoing investigations, this article represents provisional guidance on the use of HCV PIs in HIV-infected persons.

AB - In May 2011, hepatitis C virus (HCV) protease inhibitors (PIs) were approved by the US Food and Drug Administration to treat persons with genotype 1 chronic hepatitis C virus (HCV) infection, but not those dually infected with human immunodeficiency virus (HIV). Although critical safety and efficacy data are lacking, the availability of the drugs and substantial medical need justify the off-label use of HCV PIs in select HIV/HCV-coinfected persons. Pending results of ongoing investigations, this article represents provisional guidance on the use of HCV PIs in HIV-infected persons.

UR - http://www.scopus.com/inward/record.url?scp=84863393745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863393745&partnerID=8YFLogxK

U2 - 10.1093/cid/cir882

DO - 10.1093/cid/cir882

M3 - Article

C2 - 22173234

AN - SCOPUS:84863393745

SN - 1058-4838

VL - 54

SP - 979

EP - 983

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 7

ER -

Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this